Software for Predicting Liver Injury from Biologics Drug Candidates Using Data from a Human Liver Microphysiology System
Software for Predicting Liver Injury from Biologics Drug Candidates Using Data from a Human Liver Microphysiology System
批准号:
10248834
负责人:
Brett Alyn Howell
金额:
$10.65万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-03-01 至 2021-09-01
关键词:
Acute DiseaseAdaptive Immune SystemAddressAdverse eventAlbuminsAnti-Inflammatory AgentsAntibodiesAttenuatedBile AcidsBile fluidBindingBioenergeticsBiologic DevelopmentBiologicalBiological AssayBiological TestingBiomimeticsBiosensorBlood TestsBlood VesselsCellsCessation of lifeChronic DiseaseClinicalClinical DataClinical TrialsClinical Trials DesignComputer ModelsComputer softwareDataDatabase Management SystemsDevelopmentDifferential EquationEducational process of instructingEndothelial CellsEnsureEquationExposure toFc ReceptorFibrosisFluorescenceFunctional disorderGlial Growth FactorGoalsGrowth FactorHealthHepaticHepatocyteHomeostasisHumanImmuneImmune checkpoint inhibitorImmune responseIn VitroInflammationInjuryInstitutionInterleukin 6 ReceptorInterleukin-6LiverMass Spectrum AnalysisMeasuresMedicalNatural regenerationNecrosisNeuregulinsOutcomeOxidative StressPatientsPerisinusoidal SpacePharmaceutical PreparationsPharmacologic SubstancePhasePre-Clinical ModelProgram DevelopmentProtein IsoformsPublishingRecommendationResearchSafetySeriesSoftware ToolsSourceSystemTaurine CholateTerfenadineTestingValidationbasebile acid transportercase controlclinical biomarkersclinical effectcommercializationdesigndrug candidatedrug developmentexperimental studyfexofenadinehepatic acinus structurehuman dataliver functionliver injuryliver transplantationmicrophysiology systemnew technologypre-clinicalprototyperesponsesimulationsmall moleculesuccesstocilizumabtool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The goal of this project is to develop novel technology for predicting biologics-induced liver
injury such as caused by anti-inflammatory biologics such as anti-IL6 receptor antibody (e.g.,
tocilizumab), and by growth factors such as neuregulin-1β isoform, glial growth factor 2 (GGF2),
as well as by other biologics (e.g., checkpoint inhibitors). Biologics now account for more than
half of the drugs in development, and have the potential to address many acute diseases,
chronic diseases, and other unmet medical needs. Biologics-induced liver injury can manifest as
focal hepatocyte necrosis, steatosis, and fibrosis. In some cases, liver transplantation is
required for patients with biologics-induced liver injury. A significant problem is that while there
is increased development and use of biologics, there lacks tools available for the assessment of
biologics for the ability to cause biologics-induced liver injury. For example, because biologics
are typically designed specifically for human targets, standard preclinical models used for small
molecule drug development are inadequate for assessing the efficacy or safety of biologics. In
this project, we will develop novel technology that will serve as a prototype for use in testing
biologics (preclinical, clinical, or after-market) for potential to cause biologics-induced liver
injury. In developing this new technology, we will also further develop the state-of-the-art
human liver MPS (vLAMPS) to assess the liver effects of biologics from human liver cells in the
liver acinus with the aim of using vLAMPS as the eventual key source of input data for
BIOLOGXsym simulations. Additionally, we will perform validation of this new technology. Once
validated, this system will serve as a prototype that can then be expanded for commercialization
for use by our existing base of pharmaceutical company customers, regulatory agencies, and
academic institutions for teaching and academic research use.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Software for Predicting Liver Injury from Biologics Drug Candidates Using Data from a Human Liver Microphysiology System
-
批准号:10520293
-
项目类别:
-
资助金额:$14.46万
-
财政年份:2021
-
负责人:Brett Alyn Howell
-
依托单位:
海外基金